Real-world data suggests that adding CGRP inhibitors to onabotulinumtoxinA adds efficacy
Channel: Research Square
Date: 2021-10-06

Blumenfeld et al. "Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review." Pain Ther (2021). doi:10.1007/s40122-021-00264-x 
Read the article: http://dx.doi.org/10.1007/s40122-021-00264-x 
Video produced by https://www.researchsquare.com